Drug facts
Semaglutide and pregnancy
Quick answer
The label says to discontinue semaglutide in a pregnant patient who is using it for weight reduction, and to stop at least 2 months before planning to become pregnant — because semaglutide has a long half-life and takes that long to clear.
The instruction1
The reasoning the label gives is direct: weight loss offers no benefit to a pregnant patient and may cause fetal harm. Animal reproduction studies indicate there may be potential risks to the fetus, and the available human data — pharmacovigilance and trials — are described as insufficient to establish a drug-associated risk of major birth defects or miscarriage.
“Insufficient to establish” is not “shown to be safe”. The instruction follows from the absence of evidence plus the animal findings, not from a positive finding of harm in people.
Two months, not four weeks2
Section 8.3 asks for discontinuation at least 2 months before a planned pregnancy, expressly to account for the long half-life of semaglutide. That is a longer runway than people generally expect from a once-weekly injection, and it is the number to plan around.
It is also different from the equivalent tirzepatide instruction, which is built around contraception during dose escalation rather than a clearance window before conception. The two labels answer adjacent questions differently, so reading across is a mistake.
The pregnancy registry1
There is a pregnancy exposure registry that monitors outcomes in women exposed during pregnancy, and the label encourages both patients and healthcare providers to contact it. That exists because the human data are thin — reporting is how they stop being thin.
What this page is not
This reports the approved label. It is not advice about your own situation, and a compounded preparation is not exempt from any of it — see the medical disclaimer.